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Complement-Mediated Neutralization of
Dengue Virus Requires
Mannose-Binding Lectin

RESEARCH ARTICLE

Complement-Mediated Neutralization of Dengue Virus Requires
Mannose-Binding Lectin
Panisadee Avirutnan,a,b Richard E. Hauhart,a Mary A. Marovich,c Peter Garred,d John P. Atkinson,a,e,f and Michael S. Diamonda,e,f,g
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USAa; Dengue Hemorrhagic Fever Research Unit, Office for Research and
Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok-noi, Bangkok, Thailandb; Laboratory of Molecular Medicine, Division of Retrovirology,
Walter Reed Army Institute of Research and Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland, USAc; Department of Clinical
Immunology, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmarkd; Departments of Pathology and Immunology,e Molecular
Microbiology,f and the Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research,g Washington University School of Medicine, St.
Louis, Missouri, USA

ABSTRACT Mannose-binding lectin (MBL) is a key soluble pathogen recognition protein of the innate immune system that binds
specific mannose-containing glycans on the surfaces of microbial agents and initiates complement activation via the lectin pathway. Prior studies showed that MBL-dependent activation of the complement cascade neutralized insect cell-derived West Nile
virus (WNV) in cell culture and restricted pathogenesis in mice. Here, we investigated the antiviral activity of MBL in infection
by dengue virus (DENV), a related flavivirus. Using a panel of naïve sera from mouse strains deficient in different complement
components, we showed that inhibition of infection by insect cell- and mammalian cell-derived DENV was primarily dependent
on the lectin pathway. Human MBL also bound to DENV and neutralized infection of all four DENV serotypes through complement activation-dependent and -independent pathways. Experiments with human serum from naïve individuals with inherent
variation in the levels of MBL in blood showed a direct correlation between the concentration of MBL and neutralization of
DENV; samples with high levels of MBL in blood neutralized DENV more efficiently than those with lower levels. Our studies
suggest that allelic variation of MBL in humans may impact complement-dependent control of DENV pathogenesis.
IMPORTANCE Dengue virus (DENV) is a mosquito-transmitted virus that causes a spectrum of clinical disease in humans ranging

from subclinical infection to dengue hemorrhagic fever and dengue shock syndrome. Four serotypes of DENV exist, and severe
illness is usually associated with secondary infection by a different serotype. Here, we show that mannose-binding lectin (MBL),
a pattern recognition molecule that initiates the lectin pathway of complement activation, neutralized infection of all four DENV
serotypes through complement activation-dependent and -independent pathways. Moreover, we observed a direct correlation
with the concentration of MBL in human serum and neutralization of DENV infection. Our studies suggest that common genetic
polymorphisms that result in disparate levels and function of MBL in humans may impact DENV infection, pathogenesis, and
disease severity.
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D

engue virus (DENV) is a positive-sense, enveloped RNA virus
and member of the Flaviviridae family, which also includes
West Nile virus (WNV), Japanese encephalitis virus, and yellow
fever virus. DENV infection continues to spread globally with an
estimated 70 to 100 human million infections, 2.1 million clinically severe cases, and 21,000 deaths per year (1). Following mosquito inoculation, DENV infection in humans can be clinically
silent (asymptomatic) or cause syndromes ranging from a febrile
illness (classic dengue fever [DF]) to a life-threatening hemorrhage and vascular permeability syndrome (dengue hemorrhagic
fever/dengue shock syndrome [DHF/DSS]) (2). Although the
pathogenesis of DENV infection remains controversial, antibodydependent enhancement of DENV infection in Fc-␥ receptorbearing cells, effects of virulent strains, a proinflammatory cytokine storm secondary to exuberant activation of poorly lytic cross-
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reactive T cells, and excessive complement activation have been
suggested as possible mechanisms (reviewed in reference 3).
The 10.7-kb RNA genome of DENV contains genes that encode three structural proteins (capsid [C], precursor membrane
or membrane [prM/M], and envelope [E]) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5).
The mature dengue virion is an ~50-nm particle composed of a
nucleocapsid in association with the RNA genome, which is surrounded by a lipid bilayer into which the prM/M and E proteins
insert. The E protein has two potential N-linked glycosylation
sites, at Asn-67 in domain II, which is unique for the DENV complex, and Asn-153 in domain I, which is conserved in most flaviviruses (4). DENV utilizes the N-linked glycan at Asn-67 to interact with the cell surface attachment lectin DC-SIGN to facilitate
binding and entry into host cells (5, 6). DENV enters cells via
clathrin-mediated endocytosis and fuses with acidic endosomes,
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after which the viral genome penetrates into the cytoplasm of
target cells (7). Following protein translation and RNA replication, immature virions assemble within the endoplasmic reticulum (7) and pass through the Golgi and trans-Golgi network (8)
where virus maturation and cleavage of prM to M protein are
promoted by furin-like proteases (9).
Activation of the complement system occurs via three convergent pathways referred to as the classical, lectin, and alternative
pathways. The classical pathway activity is triggered by C1q binding to antigen-antibody complexes on the surfaces of pathogens.
The lectin pathway is initiated by mannose-binding lectin (MBL)
or ficolin recognition of carbohydrate structures on the surfaces of
microbes or apoptotic cells. Binding of MBL (or ficolins) activates
MBL-associated serine proteases (MASPs). While three MASP
proteins have been identified (i.e., MASP-1, -2, and -3), MASP-2
is responsible for cleavage of C4 and C2 to form the C3 convertase
C4bC2a (10). MBL has also been shown to induce C3 activation
independently of C4 and C2 (the C4 and C2 bypass pathway)
(11–13). The alternative pathway is constitutively active at low
levels through the spontaneous hydrolysis of C3 and also serves to
amplify activation of the classical and lectin pathways. The binding of C3b back to the C3 convertases of the classical and alternative pathways generates the C5 convertases. These enzymes cleave
C5 to generate the anaphylatoxin C5a and C5b, which promotes
assembly of C5b-9 membrane attack (lytic) complex.
MBL is a calcium-dependent (C-type) lectin that recognizes
adjacent equatorial monosaccharide hydroxyl groups that are
present on mannose, N-acetylglucosamine (GlcNAc), and fucose
and displayed on a range of microorganisms (14). Human MBL is
encoded by the MBL2 gene, and polymorphisms result in highly
variable MBL activity in human plasma (15). Three singlenucleotide polymorphisms (SNPs) (alleles B [codon 54], C
[codon 57], and D [codon 52]) are located in exon 1 and affect the
structural and functional integrity of the protein (15). Additional
SNPs in the promoter (H/L variants at position ⫺550 and X/Y
variants at position ⫺221) and 5= untranslated (P/Q variants at
position ⫹4) regions of the MBL2 gene influence the basal level of
MBL in serum (15). Low MBL serum levels and variant MBL
alleles have been associated with enhanced susceptibility to infection in young children and immunocompromised patients (reviewed in references 16 and 17). In adults, low serum MBL concentrations have been suggested to influence disease progression
associated with HIV, hepatitis B, hepatitis C, and herpes simplex
virus infections (18–21).
Although the complement system has been suggested to play a
role in DENV pathogenesis, in particular, during the secondary
infection (22–24), its roles in protection against DENV remain
uncertain. Here, we show that human MBL bound to insect celland mammalian cell-derived DENV and neutralized infection of
all DENV serotypes through complement activation-dependent
and -independent pathways. Moreover, we observed a direct correlation with the concentration of MBL in human serum and neutralization of DENV. Our studies suggest that allelic variation of
MBL in humans may impact complement-dependent control of
DENV infection.
RESULTS

Neutralization of insect cell- and mammalian cell-derived
DENV-2 is mediated by the lectin pathway of complement activation. A previous study showed that serum from wild-type
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C57BL/6 mice neutralized DENV-2 generated in both C6/36 insect cells and BHK21-15 mammalian cells (25). In that study,
~80% of the neutralizing activity was lost when serum from MBLA⫺/⫺ ⫻ MBL-C⫺/⫺ (MBL-A/C⫺/⫺) mice was used, suggesting
that the lectin pathway contributed to complement-mediated
neutralization of DENV serotype 2 (DENV-2) (25). However, that
study did not address whether neutralization of DENV-2 required
activation of other complement activation pathways or downstream components. To evaluate this, we pretreated insect cell
(C6/36)-derived and mammalian cell (Vero)-derived DENV-2
with naïve sera from the wild type and several congenic mouse
strains deficient in different complement components. Analogous
to results with insect cell-derived WNV (25), neutralization of
both insect cell- and mammalian cell-derived DENV-2 was dependent on MBL and MBL-associated serine protease 2 (MASP2), but not C1q or C5 (Fig. 1A and C). Thus, the classical complement activation pathway and the formation of membrane attack
complex were not necessary for neutralization of DENV-2 by serum. Because an absence of both C3 and C4 (C3⫺/⫺ ⫻ C4⫺/⫺
double knockout [DKO]) almost abrogated the inhibitory effect
of serum, MBL-dependent neutralization of DENV-2 required
activation of the complement system; however, deficiencies in either C3 or C4 resulted in only partial loss of neutralization phenotypes. This suggests that DENV-2 neutralization by MBL occurs through both the canonical lectin (C4-dependent) pathway
and the C4 and C2 bypass pathways (11–13) of complement activation (Fig. 1E).
In the absence of factor B (fB) or factor D (fD), DENV-2 neutralization was also partially inhibited, suggesting a contribution
from the alternative pathway, probably via the amplification loop
that results in greater deposition of C3 on the virion surface
(Fig. 1E). Serum from RAG1⫺/⫺ mice neutralized DENV infection
to a level similar to that from wild-type mice; as RAG1⫺/⫺ mice
lack B and T cells, this establishes that natural antibody does not
contribute significantly to the serum-dependent neutralization of
DENV-2. Notably, antibody-independent serum neutralization
of DENV-2 was efficient, as even highly diluted (1.25% of neat)
serum neutralized 60 to 70% of infection by DENV-2 (Fig. 1B and
D). MBL-dependent neutralization of both insect cell- and mammalian cell-derived DENV-2 by mouse serum was confirmed by a
complete loss of neutralization in the presence of excess soluble
mannan, a competitor for MBL binding (Fig. 1B and D).
MBL directly binds and neutralizes insect cell-derived
DENV-2 independent of complement activation. Whereas neutralization of WNV by MBL occurred with insect cell-derived virus, but not mammalian cell-derived virus (25), both forms of
DENV-2 were susceptible to MBL-dependent complementmediated inhibition. However, neutralization of insect cellderived DENV-2 by naïve wild-type C57BL/6 mouse serum was
more efficient than mammalian cell-derived DENV-2 (100% versus 60 to 80% neutralization at 10% serum concentration, respectively; P ⬍ 0.0001) (Fig. 1A to D). This phenotype is likely due to
modifications of high-mannose carbohydrate moieties on the
structural proteins on the surfaces of DENV-2 virions produced in
mammalian cells (26) resulting in less efficient recognition by
MBL. To test for direct binding of MBL to DENV-2, we developed
a capture enzyme-linked immunosorbent assay (ELISA) in which
infectious virus was bound to wells of a microtiter plate coated
with anti-DENV prM mutant monoclonal antibody (MAb). Purified recombinant MBL bound efficiently to immobilized insect
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FIG 1 Neutralization of insect cell- and mammalian cell-derived DENV-2 by mouse serum is mediated by the lectin pathway. (A and C) Neutralization of C6/36
cell-derived (A) or Vero cell-derived (C) DENV-2 in the presence of 10% (vol/vol) complement-deficient serum. DENV was incubated with naïve serum from
wild-type (WT) mice or complement-deficient (MBL-A⫺/⫺ ⫻ MBL-C⫺/⫺ [MBL A/C⫺/⫺] MASP2⫺/⫺, C1q⫺/⫺, C4⫺/⫺, C3⫺/⫺, C3⫺/⫺ ⫻ C4⫺/⫺ [C3/C4] DKO,
C5⫺/⫺, fB⫺/⫺, or fD⫺/⫺) or antibody-deficient (RAG1⫺/⫺) mice prior to addition to a monolayer of BHK21-15 cells. Infectivity was determined 4 days later by
plaque assay. Data are presented as the percent neutralization by a given complement-deficient or antibody-deficient serum compared to wild-type C57BL/6
serum. Error bars indicate standard errors of the means (SEM) for up to 6 independent experiments with each condition performed in duplicate. Values that are
significantly different from the value for wild-type C57BL/6 serum are indicated by asterisks as follows: *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001. (B and D) Serum
neutralization of C6/36 cell-derived (B) or Vero cell-derived (D) DENV is abolished in the presence of mannan. DENV was preincubated with an increasing
percentage of wild-type serum in the presence or absence of mannan (100 g/ml). The percentage of neutralization was calculated based on reduction of the
number of plaques for a given condition compared to heat-inactivated (HI) wild-type serum. Error bars indicate SEM from 3 independent experiments
performed in duplicate. Values that are significantly different from the value for the wild type are indicated by asterisks and brackets as follows: *, P ⬍ 0.05; **,
P ⬍ 0.01; ***, P ⬍ 0.001. (E) Model of DENV neutralization by complement. MBL binding to the virion surface initiates lectin pathway activation resulting in
deposition of C4b and C3b. Binding of MBL also activates MASPs that directly cleave C3 without activation of C4 and C2 (the C4 and C2 bypass pathway). The
alternative pathway amplification loop serves to generate more C3b deposition on the virus.

cell-derived DENV-2 in a dose-dependent manner, and as expected, binding was Ca2⫹ dependent and blocked by soluble mannan (Fig. 2A). The specificity of the interaction was confirmed by
an absence of signal when an isotype control (anti-hepatitis C
virus E2 protein) MAb was used as the capture antibody. We next
compared the relative binding of MBL to insect cell- and mammalian cell-derived DENV-2. Equivalent amounts of both viruses,
as judged by a DENV E-protein-specific MAb that bound captured virions (Fig. 2C), were interrogated for binding to MBL by
ELISA. Notably, purified MBL preferentially bound to insect cellderived DENV-2 at all concentrations tested (P ⬍ 0.05 [Fig. 2B]).

November/December 2011 Volume 2 Issue 6 e00276-11

The dose-dependent binding of purified MBL to mammalian cellderived DENV-2 was also Ca2⫹ dependent and inhibited by soluble mannan.
MBL exists as an oligomer of homotrimers (14). Binding of
higher-order oligomeric MBL to viruses could cause steric interference between the structural proteins on the virion surface and
their cognate ligands, and thus, restrict infection of target cells. To
test this, we pretreated insect cell-derived DENV-2 with purified
MBL, which forms oligomers similar to native human MBL (27),
before addition to a monolayer of BHK21-15 cells. Binding of
physiological concentrations of MBL to insect cell-derived
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FIG 2 Human MBL neutralizes insect cell-derived DENV-2 independent of complement activation. (A and B) MBL binds to DENV-2. C6/36 cell-derived
DENV-2 (A) or both C6/36 cell-derived and Vero cell-derived DENV-2 (B) virions were captured on a microtiter plate using an anti-DENV prM protein-specific
MAb (2H2) or isotype control anti-hepatitis C virus (anti-HCV) E2 MAb (H77.16) and incubated with an increasing concentration of purified human MBL.
MBL binding was detected with an anti-MBL specific MAb and inhibited by the presence of 10 mM EDTA or 100 g/ml mannan. Error bars indicate SEM for
up to 6 independent experiments. Black asterisks indicate statistical differences compared to EDTA-treated samples. Grey asterisks denote values of C6/36
cell-derived DENV binding to MBL that are different from those of Vero cell-derived DENV-2. O.D. 450 nm, optical density at 450 nm. (C) In parallel
experiments, captured DENV virions derived from C6/36 or Vero cells were detected with an anti-DENV E-protein-specific MAb (4G2). (D and F) Human MBL
restricts DENV-2 derived from insect cells but not DENV-2 derived from mammalian cells in the absence of complement activation. DENV-2 derived from
C6/36 cells (D) and Vero cells (F) were incubated with increasing concentrations of purified MBL prior to addition to a monolayer of BHK21-15 cells. After
4 days, infectivity was determined by plaque assay. Data are presented as the percent neutralization (percent reduction of plaques compared to the number of
plaques in buffer alone in a given condition). (E) MBL-mediated neutralization of insect-derived DENV-2 is enhanced by complement activation. C6/36
cell-derived DENV-2 was preincubated with serum from MBL-A/C⫺/⫺ mice in the presence or absence of purified MBL at the indicated concentrations, with or
without mannan (100 g/ml). The percent neutralization was calculated based on the percent reduction of plaques in a given condition compared to the number
of plaques in MBL-A/C⫺/⫺ serum. Error bars indicate SEM from 2 to 4 independent experiments performed in duplicate. Values that are significantly different
are indicated by asterisks as follows: *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001.

DENV-2 in the absence of any other complement components
neutralized infection up to 65% (Fig. 2D). Nonetheless, the efficiency of neutralization increased significantly (2- to 6-fold [P ⬍
0.001]) in the presence of other complement components in serum from MBL-A/C⫺/⫺ mice, especially at low concentrations of
purified MBL (e.g., 0.03 g/ml) (Fig. 2E). As expected, soluble
mannan competed with binding of purified MBL to DENV and
inhibited both complement-independent (Fig. 2D) and
complement-dependent (Fig. 2E) neutralization of insect cellderived DENV-2. In contrast, purified MBL failed to directly neutralize DENV-2 propagated in several mammalian cell types, including Vero cells, primary human monocyte-derived dendritic
cells (DC), and primary human peripheral blood monocytes, or
WNV that was produced in insect and mammalian cells, even with
concentrations of MBL as high as 30 g/ml (~10-fold above the
physiological level) (Fig. 2F; see Fig. S1 in the supplemental material). In contrast to human MBL, purified mouse MBL inhibited
insect cell-derived DENV-2 poorly without complement activation, although neutralizing activity was greatly enhanced in the
presence of other complement components (Fig. S2). In combination with the 2-fold-lower blood levels of MBL in MASP-2⫺/⫺
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mice (data not shown), these results begin to explain the lack of
neutralizing activity in serum from MASP-2⫺/⫺ mice (Fig. 1A).
Flavivirus virions are dynamic structures, and their “breathing” at higher temperatures impacts antibody neutralization of
WNV and DENV by modulating epitope accessibility (28, 29), a
phenomenon that could be important for antiviral immunity in
the context of the febrile response. Consistent with this, binding of
purified MBL to DENV at 37°C and 40°C increased neutralization
of insect cell-derived DENV-2 (room temperature versus 37°C, P
⫽ 0.02; room temperature versus 40°C, P ⫽ 0.0009; 37°C versus
40°C, P ⬍ 0.0001), but not mammalian cell-derived DENV-2 in
the absence of additional complement components (Fig. 3A and
B); this temperature effect was specific to MBL, as it was abolished
by the addition of soluble mannan and did not occur with an
irrelevant protein, bovine serum albumin (BSA), or another collectin, C1q.
Neutralization of insect cell-derived DENV-2 by human serum depends on the concentration of MBL. We next assessed the
relevance of our findings with human serum. Initially, sera from
two healthy adult DENV-naïve volunteers were assayed for neutralization of DENV-2. Consistent with results with wild-type
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FIG 3 Complement-independent human MBL-mediated neutralization of
insect cell-derived DENV-2 is more efficient at higher temperatures. C6/36
cell-derived DENV-2 (A) or Vero cell-derived DENV-2 (B) was incubated
with purified human MBL in the presence or absence of 100 g/ml mannan or
equivalent concentrations of BSA or C1q prior to addition to BHK21-15 cells
at the indicated temperatures (RT, room temperature). The percent neutralization was calculated based on the percent reduction of the number of plaques
in a given condition compared to the value in buffer alone. Error bars indicate
SEM from 3 to 6 independent experiments performed in duplicate. Values that
are significantly different are indicated by asterisks and brackets as follows: *, P
⬍ 0.05; ***, P ⬍ 0.001.

mouse serum (Fig. 1B and D), insect cell-derived DENV-2
(Fig. 4A) and mammalian cell-derived DENV-2 (Fig. 4C) were
neutralized by human serum. Serum inhibition of DENV-2 infection was MBL dependent, as neutralization was abolished in the
presence of soluble mannose. Mannose, a second competitor ligand for MBL, was used instead of mannan, because anti-mannan
antibodies are ubiquitously present in human sera (30, 31). MBLdependent neutralization of mammalian cell-derived DENV-2 by
human serum was less effective relative to insect cell-derived
DENV-2 (for donor 1, at 10% and 20% serum, P ⬍ 0.0001, at 35%
serum, P ⫽ 0.004; for donor 2, at 10% serum, P ⫽ 0.03, at 20%
serum, P ⫽ 0.04, at 35% serum, P ⫽ 0.001). We also noticed that
serum from donor 1 neutralized DENV-2 more efficiently than
that of donor 2. Blood MBL levels in humans vary considerably
(up to 1,000-fold) due to at least five common genetic polymorphisms in the human MBL2 gene (15). We speculated that the
inefficient neutralization of DENV-2 by serum from donor 2 was
due to a lower serum MBL concentration. Using a commercial
ELISA, the concentrations of MBL in sera from donors 1 and 2
were measured as 7,950 and 1,380 ng/ml, respectively. Indeed,
reconstitution of serum from donor 2 with purified MBL to the
level of donor 1 resulted in neutralization of insect cell-derived
DENV-2 to a degree similar to that of serum from donor 1
(Fig. 4B). To our surprise, the addition of even high concentrations (5.4 g/ml) of purified MBL to serum from donor 2 did not
neutralize mammalian cell-derived DENV-2 (Fig. 4D). However,
the addition of increasing percentages of fresh (Fig. 4E) or heat-
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inactivated (Fig. 4F) serum from donor 1 to serum from donor 2
resulted in neutralization of mammalian cell-derived DENV-2.
This result was abolished by soluble mannose, establishing that
neutralization of mammalian cell-derived DENV-2 by donor 2
required MBL from the serum from donor 1 in particular (Fig. 4E
and F).
To further investigate how the concentration of MBL impacts
the ability of human serum to neutralize DENV-2, we obtained
sera from fifteen additional healthy adult volunteers, including
five donors with known polymorphisms (associated with changes
in the level, structure, and function of the protein) in the MBL2
gene (15) (Table 1). We first measured the concentrations of MBL
in these sera (Fig. 5A). MBL levels varied widely, ranging from
⬍2 ng/ml to 8 g/ml. We next tested whether native forms of
MBL in human serum bound DENV-2. Similar to results with
purified human MBL (Fig. 2A and B), MBL in serum bound to
immobilized insect cell-derived DENV-2 virions (Fig. 5D). Notably, the degree of binding to DENV-2 reflected the concentrations
of MBL in different serum samples (Fig. 5A and D), as a positive
correlation was observed (R2 ⫽ 0.868 and P ⬍ 0.0001 [Fig. 5G]).
As expected, MBL concentrations also modulated the efficiency of
serum-dependent neutralization of DENV-2; sera from individuals with higher blood MBL levels neutralized virus more effectively
than those with lower MBL levels (Fig. 5E). However, weakly neutralizing activity observed in some serum samples also could be
due to deficiencies of other complement components, especially
C4 whose functional level is influenced by several factors, including the number of copies of the C4A and C4B genes (32). To
evaluate this, functional C4 and total complement hemolytic activity (CH50 levels [dose of complement that lyses 50% of a red
blood cell suspension]) in sera were measured. In contrast to serum MBL concentrations (Fig. 5A), no significant difference (P ⬎
0.05) in functional C4 (Fig. 5B) and CH50 (Fig. 5C) levels was
observed among donors. Importantly, neutralization of DENV-2
by sera from all donors except donors 8 and 11 was antibody
independent and MBL specific, as the addition of excess soluble
mannose abrogated the neutralizing activities (Fig. 5F). The neutralization of DENV-2 by sera from donors 8 and 11, which later
were determined to contain DENV-2 specific IgG (data not
shown), was MBL independent, and likely occurred through activation of the classical complement pathway. Additionally, a high
level of anti-DENV-2 specific IgG in serum from donor 8 may
have interfered with the serum MBL binding to DENV-2 virions,
resulting in a relatively low signal in the capture ELISA (Fig. 5D).
Overall, a positive correlation was observed between neutralization and serum MBL levels (R2 ⫽ 0.662 and P ⫽ 0.0002 [Fig. 5H]).
Notably, the sera from three individuals (donors 14, 15, and 16)
carrying the structural variant MBL alleles (B, C, or D, and thus
markedly reduced MBL levels) also had very low neutralizing activities (Table 1). Because mammalian cell-derived DENV-2 was
less efficiently inhibited by human serum (Fig. 4A and C), a higher
percentage of serum (35%) was used in neutralization assays in the
absence (see Fig. S3A in the supplemental material) or presence
(Fig. S3B) of mannose. Despite a lower level of inhibition, a positive correlation was also present between serum MBL levels and
neutralization of mammalian cell-derived DENV-2 (R2 ⫽ 0.623
and P ⫽ 0.0005 [Fig. S3C]).
MBL neutralizes other DENV serotypes through
complement-dependent and -independent mechanisms. The
DENV complex comprises four antigenically related serotypes
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FIG 4 Neutralization of insect cell- and mammalian cell-derived DENV-2 by human serum depends on the lectin pathway. (A and C) Lectin pathway-mediated
neutralization of DENV-2 by human serum depends on the concentration of MBL. C6/36 cell-derived (A) or Vero cell-derived (C) DENV-2 was preincubated
with increasing percentages of naïve human serum (donor 1 or donor 2) in the absence or presence of 1 M mannose. Neutralization was calculated based on the
reduction of the number of plaques in a given condition compared to heat-inactivated (HI) serum. (B and D) Purified MBL enhances neutralizing efficiency of
human serum against insect cell- but not mammalian cell-derived DENV-2. C6/36 cell-derived (B) or Vero cell-derived (D) DENV-2 was preincubated with 10%
(vol/vol) serum from donor 2 in the absence or presence of increasing concentrations of purified MBL, with or without 1 M mannose. Neutralization was
calculated based on reduction of the number of plaques in a given condition compared to the value in heat-inactivated serum from donor 2. (E and F) MBL
present in strongly neutralizing human serum restores the inhibitory capacity of weakly neutralizing human serum against mammalian cell-derived DENV-2.
Vero cell-derived DENV-2 was preincubated with 10% (vol/vol) serum from donor 2 in the absence or presence of an increasing percentage of fresh (E) or
heat-inactivated (F) serum from donor 1, with or without 1 M mannose. Neutralization was calculated based on the reduction of the number of plaques in a given
condition compared to the value for heat-inactivated serum from donor 2. Error bars indicate SEM for 3 to 6 independent experiments performed in duplicate.
Values that are statistically significant different are indicated by asterisks and brackets as follows: **, P ⬍ 0.01; ***, P ⬍ 0.001.

with significant diversity at the amino acid level (between 25 and
40%) (33). We therefore extended our studies with MBL to the
other serotypes of DENV. Consistent with results with DENV-2,
MBL neutralized insect cell-derived DENV-1, -3, and -4 via
complement-dependent (Fig. 6A) and complement-independent
(Fig. 6B) mechanisms. Naïve human sera from donor 1, which
contained a higher level of MBL neutralized insect cell-derived
DENV-1 and -3 more efficiently than sera from donor 2 (P ⬍
0.001 for DENV-1 and P ⬍ 0.01 for DENV-3) (Fig. 6C). However,
sera from donor 1 (despite having a high concentration of MBL
[~8 g/ml]) and donor 2 failed to neutralize insect cell-derived
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DENV-4 (Fig. 6C). Nonetheless, reconstitution of serum from
donor 2 with purified human MBL (1.36 g/ml) neutralized up to
90% of infection by DENV-1, -3, and -4 (Fig. 6C), confirming that
the complement-mediated neutralization of insect cell-derived
DENV by human serum depended on MBL.
DISCUSSION

MBL, a key pattern recognition plasma protein of the complement
system, restricts pathogen infection by several mechanisms, including direct opsonization, activation of the lectin complement
pathway, regulation of cytokine production, and amplification of
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TABLE 1 MBL-dependent neutralizing activity in sera with known polymorphisms in the MBL2 gene
Donor no.

Polymorphisms in the MBL2 genea

Serum MBL level (ng/ml)b

Serum MBL binding to DENV (OD at 450 nm)c

% neutralization of DENVd

12
13
14
15
16

HYPA/LXPA
HYPA/LXPA
LYQA/LYQC
LYPB/HYPD
HYPD/HYPD

3,552
2,121
219
⬍2
⬍2

0.209 ⫾ 0.043
0.164 ⫾ 0.049
0.037 ⫾ 0.014
0.005 ⫾ 0.003
0.019 ⫾ 0.018

73.6 ⫾ 11.1
32.3 ⫾ 14.1
21.4 ⫾ 13.7
16.9 ⫾ 11.0
11.9 ⫾ 1.5

a Single-nucleotide polymorphisms (SNPs) in the MBL2 gene include the following: G-to-C nucleotide substitutions at positions ⫺550 (alleles H/L) and ⫺221 (alleles X/Y) in the
promoter region; C-to-T nucleotide substitution at position ⫹4 (alleles P/Q) in the 5= noncoding region; single-nucleotide substitutions at codons 52 (C to T [allele D]), 54 (G to A
[allele B]), and 57 (G to A [allele C]) in exon 1. The normal allele is referred to as A.
b Serum MBL levels were measured by a quantitative capture ELISA as described in Materials and Methods.
c Serum MBL binding to insect cell-derived DENV-2 virions was determined using a capture ELISA as described in the legend to Fig. 5D. Data are the means ⫾ standard deviations
(SD) for four independent experiments.
d MBL dependent-serum neutralization of insect cell-derived DENV-2 was performed as described in the legend to Fig. 5E. Neutralization was calculated based on reduction of the
number of plaques compared to the value for heat-inactivated serum. Data are the means ⫾ SD for three independent experiments.

adaptive immunity (14). Prior studies established that MBL controls WNV infection in mice by binding N-linked glycans on viral
structural proteins and activating the lectin pathway of complement (25, 34). The results of our studies here show that MBL also
restricts infection by DENV, a related flavivirus. Human MBL
inhibited infection of all DENV serotypes by both complementdependent and complement-independent mechanisms. MBLmediated neutralization of DENV, however, was more efficient
with virus generated in insect cells compared to virus generated in
mammalian cells. Finally, the concentration of MBL in human
serum, which varies among individuals due to common genetic
polymorphisms in the human MBL2 gene (15), directly impacted
neutralization of DENV.
Antibody-independent complement-mediated neutralization
of both insect cell- and mammalian cell-derived DENV exclusively required MBL. Neutralization of DENV by MBL was dependent on MASP-2, partially dependent on C3, C4, factor D, and
factor B, yet independent of C1q and C5. The absence of C3 or C4
alone only partially reduced neutralization, whereas a combined
C3 and C4 deficiency nearly abolished serum neutralization. This
suggests that direct binding of MBL neutralizes DENV through
both the canonical lectin pathway and the C4 and C2 bypass pathways; in the latter, MBL binding directly triggers C3 activation
independent of C4 and C2 (11–13), resulting in deposition of C4
and C3 on the virion surface. The alternative pathway of complement activation partially contributed to DENV neutralization,
presumably via the amplification loop, which leads to greater deposition of C3 on the virion surface (Fig. 1E).
During natural DENV infection, following the bite of an infected mosquito, the human host first encounters insect cellgenerated virus. Subsequent rounds of infection produce virus
from human cells. In contrast to that observed with WNV (25),
MBL in serum neutralized both insect cell- and mammalian cellderived DENV, suggesting a role for MBL in controlling both
stages of DENV infection. MBL recognizes adjacent equatorial
monosaccharide hydroxyl groups that are present on mannose,
N-acetylglucosamine (GlcNAc), and fucose, which are commonly
found on microorganisms (14). More efficient neutralization of
DENV (both insect cell and mammalian cell derived) compared to
neutralization of WNV (only insect cell derived) by MBL may be
due to the additional N-linked glycan at Asn-67, which confers
binding to the attachment factor DC-SIGN (5) and is unique to
DENV among flaviviruses. The results of our experiments also
established that MBL can bind and neutralize insect cell-derived
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DENV directly in the absence of further complement activation;
this did not occur with mammalian cell-derived DENV.
While MBL has been reported to inhibit infection of several
types of viruses, including filoviruses, influenza virus, hepatitis C
virus (HCV), herpes simplex virus, human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus, and
WNV, in most studies, neutralization required complement activation (25, 35–41). However, in our experiments, efficient recognition of insect cell-derived DENV by purified human MBL was
sufficient to neutralize the virus of all four serotypes independent
of complement activation. As MBL is a multimeric molecule that
comprises two to six subunits of a triple helix of three identical
32-kDa polypeptide chains (14), binding of MBL to DENV may
impair host cell attachment and/or entry. For example, binding of
MBL to the surface glycoproteins of influenza A virus, HCV, and
HIV in a complement-free system blocked virus attachment to
target cells (36, 42, 43). Lack of direct neutralization of mammalian cell-derived DENV and insect cell- and mammalian cellderived WNV by MBL (despite saturating concentrations [30 g/
ml]) in the absence of complement suggests that a higher number
of MBL-binding sites are available on insect cell-derived DENV,
which is sufficient to reach the threshold required for neutralization. In comparison, binding of fewer molecules of MBL (even as
low as 30 ng/ml [1,000-fold lower]) could trigger lectin and alternative pathway activation, which deposits C4 and C3 on the virion
surface (25), and promotes neutralization. Deposition of C4b and
C3b on virions by MBL-dependent lectin pathway activation inhibited WNV infection, in part, by blocking viral fusion (25), possibly by interfering with the requisite pH-dependent structural
rearrangements.
In humans, the concentration of MBL in plasma varies greatly,
ranging from a few nanograms per milliliter to 10,000 ng/ml due
to polymorphisms in the promoter and exon 1 of the MBL2 gene
(15). Genetic variation in the MBL2 gene results in up to 30% of
the human population having low blood MBL levels (⬍500 ng/
ml), which has been linked with an increased risk and severity of
several infectious diseases (reviewed in references 17 and 44). Our
in vitro results with DENV are consistent with this observation
and provide a mechanism for why this occurs. The concept that
levels of complement proteins could impact DENV severity is not
new, as it was raised in seminal studies showing lower levels of C4
and C3 in patients with DHF/DSS (23). Complement genetics
(including MBL variation) and the susceptibility of DENV infection have also been examined. While one study observed an in-
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FIG 5 Neutralization of insect cell-derived DENV-2 by human serum is dependent on the concentration of MBL. (A to C) Sera from 17 healthy adult individuals
were collected and assayed for the levels of MBL (A), C4 (B), and total hemolytic complement activity CH50 (C). Error bars indicate SEM for 2 to 4 independent
experiments. (D and G) MBL in human serum binds to C6/36 cell-derived DENV-2 and correlates with serum MBL concentration. DENV virions were captured
on a microtiter plate and incubated with a 1:4 dilution of sera from 17 donors (D). Specific binding of serum MBL to C6/36 cell-derived DENV-2 was calculated
by subtracting the OD at 450 nm of serum in the presence of 10 mM EDTA from the OD at 450 nm of serum. Error bars indicate SEM from 4 independent
experiments. (G) The correlation coefficient for MBL binding to C6/36 cell-derived DENV-2 from each individual (except donors 8 and 11) and the serum MBL
level was estimated. The linear regression, correlation coefficient (R2), and P value are presented in the graph. Error bars indicate SEM for 2 to 4 independent
experiments. (E, F, and H) Neutralization of DENV-2 by human serum correlates with serum MBL levels. C6/36 cell-derived DENV-2 was preincubated with
10% (vol/vol) serum from each donor in the absence (E) or presence (F) of 1 M mannose. Neutralization was calculated based on the reduction of the number
of plaques compared to the value for heat-inactivated serum. Error bars indicate SEM from 3 to 5 independent experiments. (H) The correlation coefficient
between the percent neutralization in the absence of mannose by serum from each individual (except donor 8 and 11) and serum MBL levels was calculated. The
linear regression, correlation coefficient (R2), and P value are presented in the graph. Error bars indicate SEM for 3 to 5 independent experiments.

creased risk of DENV-induced thrombocytopenia with wild-type
but not low-producer MBL genotypes (45), another found no
effect of MBL variation on the risk of severe dengue infection (46).
However, the vast majority of patients from these studies were
experiencing secondary dengue infection, when cross-reactive
complement-fixing antibodies are present. MBL opsonization
could protect against primary DENV infection (when anti-DENV
antibodies are absent or at low levels) yet be overshadowed during
secondary DENV infection when antibody-mediated classical
pathway-dependent complement activation occurs. At present, it
is poorly understood why the majority (up to almost 90% in some
studies) of primary DENV infections are asymptomatic (47–49).
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Prospective cohort studies in children with preillness and acute
plasma samples will be required to assess how a relative MBL
deficiency impacts the severity of a primary DENV infection.
Somewhat surprisingly, MBL in serum from donor 1 variably
neutralized four serotypes of insect-cell derived DENV. Differential binding and neutralization of diverse HCV genotypes by MBL
have also been observed (36). Among the DENV serotypes,
DENV-4 is the most antigenically distinct (50). As the recognition
of targets by MBL relies on surface-exposed carbohydrates, the
extent of N-linked glycosylation and the spatial arrangement of
glycans could influence susceptibility to MBL recognition and
neutralization. Alternatively, differential maturation among
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DENV serotypes could affect retention and display of the prM
glycoprotein on the virion and impact MBL binding and neutralization. Studies with different DENV serotypes produced in cells
that overexpress furin are planned to address how maturation
impacts MBL-dependent neutralization.
Not all of our DENV neutralization studies with human serum
containing different levels of MBL were readily explained.
Whereas reconstitution of serum from donor 2 with purified MBL
restored neutralization of insect cell-derived DENV-2, addition of
even higher concentrations of purified MBL to serum from donor
2 failed to inhibit mammalian cell-derived DENV-2, yet complementation with low concentrations of serum from donor 1 did.
Although additional studies are warranted, purified human MBL
may interact with downstream complement proteins (e.g.,
MASP-2) in the serum from donor 2, albeit with lower affinity
compared to the native MBL from donor 1. As another example,
we also observed differential neutralizing capacity of sera from
individuals (donors 3, 7, and 12 or donors 6, 10, and 13) with
similar plasma MBL levels and no difference in C4 levels and
CH50 activity. In contrast to wild-type MBL, which comprises a
mixture of higher-order 200- to 700-kDa oligomers, some MBL
point mutation variants preferentially form low-molecular-mass
(120- to 130-kDa) complexes in circulation; these complexes do
not bind well to mannan and activate the lectin pathway less efficiently (15). Variability in the oligomeric state of circulating MBL
among individuals independently could contribute to differences
in relative neutralization in the setting of similar MBL levels. Ficolin is another pattern recognition molecule of the lectin pathway whose blood levels vary among individuals due to genetic
polymorphisms (51). As serum MASPs also associate with ficolins
(10), variation in ficolin levels could differentially sequester
MASPs and explain some of the discordant results.
Overall, our studies support the hypothesis that MBL contributes to protection against DENV infection. The interplay between
allelic variations of MBL, the specific viral serotypes, and the type
of infection (primary versus secondary) could impact the severity
of DENV infection. Further prospective clinical studies are warranted to investigate the precise role of MBL deficiency and its
effects on DENV infection in humans.
FIG 6 MBL neutralizes insect cell-derived DENV serotypes 1, 3, and 4. (A)
C6/36 cell-derived DENV-1, -3, and -4 were preincubated with 2% (vol/vol)
wild-type mouse serum in the presence or absence of mannan (100 g/ml).
The virus was added to Vero cells, and infectivity was determined 48 hours (for
DENV-1 and -4) or 60 hours (for DENV-3) later by a focus-forming assay.
Neutralization was calculated based on reduction of the number of foci in a
given condition compared to the value in heat-inactivated (HI) serum. Error
bars indicate SEM for 5 or 6 independent experiments performed in duplicate.
(B) C6/36 cell-derived DENV-1, -3, and -4 were incubated with purified human MBL (3 g/ml) in the presence or absence of mannan (100 g/ml) prior
to addition to a monolayer of Vero cells. Data are presented as percent neutralization (percent reduction of the number of foci compared to the value in
buffer alone) in a given condition. Error bars indicate SEM for 5 independent
experiments performed in duplicate. (C) C6/36 cell-derived DENV-1, -3, and
-4 were preincubated with 10% (vol/vol) naïve human serum (donor 1 or
donor 2) in the absence or presence of 1 M mannose or 1.36 g/ml purified
human MBL. Neutralization was calculated based on reduction of the number
of foci compared to the value in heat-inactivated (HI) serum. Error bars indicate SEM for 5 independent experiments performed in duplicate. Values that
are significantly different are indicated by brackets and asterisks as follows: *, P
⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001.
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MATERIALS AND METHODS
Cell lines, sera, and reagents. BHK21-15 and Vero T144 cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) supplemented
with 10% fetal bovine serum (FBS) (Omega Scientific), 100 IU/ml penicillin, 100 g/ml streptomycin, 10 mM HEPES (pH 7.3), and 10 mM
nonessential amino acids (Cellgro) at 37°C. C6/36 Aedes albopictus mosquito cells were grown in Leibovitz-15 (Sigma) medium supplemented
with 10% FBS and 10 mM HEPES at 25°C. Fresh human blood samples
were collected in glass tubes and allowed to clot at room temperature for
30 minutes. After centrifugation (830 ⫻ g) for 10 minutes at 4°C, sera were
aliquoted and frozen at ⫺80°C. Serum samples were thawed on the day of
analysis. Sera from wild-type C57BL/6 mice and congenic complementdeficient (MBL-A/C⫺/⫺, MASP-2⫺/⫺, C1q⫺/⫺, C3⫺/⫺, C4⫺/⫺, C3⫺/⫺ ⫻
C4⫺/⫺ [C3/C4 DKO], C5⫺/⫺, fB⫺/⫺, and fD⫺/⫺) and antibody-deficient
(RAG1⫺/⫺) mice were obtained as previously described (25). Enzon Pharmaceuticals provided the purified recombinant human MBL (27) as a
generous gift.
Blood samples from subjects in the United States were obtained with
informed consent and approval by the Washington University institutional review board. Some human samples were obtained in Denmark
from anonymous blood donors with informed consent according to the
Danish law of blood donation.
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MBL genotyping. The single-nucleotide polymorphisms in the promoter region at positions ⫺550 (H/L variants) and ⫺221 (X/Y variants),
in the 5= noncoding region at position ⫹4 (P/Q variants) and in codons 54
(allele B), 57 (allele C), and 52 (allele D) in exon 1 of the MBL2 gene were
identified as previously described (52).
Virus stocks. DENV serotype 1 (DENV-1) (16007), serotype 2
(DENV-2) (16681), serotype 3 (DENV-3) (UNC 3043), serotype 4
(DENV-4) (1036), and WNV (New York 1999) were propagated in C6/36
or Vero cells to generate insect cell- or mammalian cell-derived virus
stock, respectively. In some experiments, DENV-2 was cultured in freshly
isolated human peripheral blood monocytes or monocyte-derived dendritic cells as previously described (53).
Virus neutralization. DENV-2 or WNV (102 PFU of DENV-2;
103 PFU of WNV) was incubated with naïve mouse or human serum
(fresh or heat inactivated at 56°C for 30 min) or purified recombinant
human MBL diluted in gelatin veronal buffer with Mg2⫹ and Ca2⫹
(GVB⫹⫹; Complement Technology) for 1 h at 37°C. Samples were added
to a monolayer of BHK21-15 cells and incubated for 1 h at 37°C. Cells
were washed, overlaid with 1% low-melting-point agarose (SeaPlaque;
Lonza) in minimal essential medium (MEM) containing 4% fetal bovine
serum (FBS), and cultured for 3 (WNV) or 4 (DENV-2) days at 37°C.
Following formaldehyde (10%) fixation and crystal violet staining,
plaques were scored visually. For studies with DENV-1, -3, and -4, 102 to
103 focus-forming units (FFU) of virus were incubated with serum or
purified recombinant human MBL for 1 h at 37°C as described above.
Samples were added to a monolayer of Vero cells and incubated for 1 h at
37°C. Cells were washed and overlaid with 1% methylcellulose mixed with
DMEM containing 5% FBS and incubated for 48 (DENV-1 and -4) or 60
(DENV-3) hours. Monolayers were washed thrice with PBS to remove
methylcellulose, fixed with 1% paraformaldehyde in PBS for 10 minutes
at room temperature, rinsed, and permeabilized in Perm Wash
(phosphate-buffered saline [PBS], 0.1% saponin, and 0.1% BSA).
Infected-cell foci were stained by incubating cells with the flavivirus crossreactive MAb WNV-E18 (54) (1 g/ml) and quantitated as described
previously (34). In some experiments, viruses were incubated with serum
or MBL in the presence or absence of 100 g/ml mannan or 1 M mannose
prior to the addition to cells.
MBL-DENV capture ELISA. MBL binding to DENV was evaluated
using a virus capture ELISA with MAb-coated wells on microtiter plates as
described previously (25) with the following modifications: the wells on
microtiter plates were adsorbed with an anti-DENV prM protein-specific
MAb 2H2 (55) or an isotype control (IgG2a) anti-hepatitis C virus E2
MAb H77.16 (56) (10 g/ml in PBS) at 4°C overnight. DENV-2 stocks
were diluted in DMEM to 5 ⫻ 105 PFU/ml and added to wells. The wells
on the plates were washed and then incubated with increasing concentrations of purified human recombinant MBL diluted in binding buffer
(20 mM Tris-HCl [pH 7.4], 0.05% Tween 20, 0.1% [wt/vol] BSA, 1 M
NaCl, and 10 mM CaCl2). The wells on the plates were washed, incubated
sequentially with biotin-conjugated mouse anti-human MBL MAb (Cedarlane), horseradish peroxidase (HRP)-conjugated streptavidin, and developed with 3,3=,5,5=-tetramethylbenzidine (TMB) substrate (DAKO).
The optical density (OD) at 450 nm was determined by a 96-well plate
reader (Genio Pro; Tecan Instruments). In some experiments, captured
DENV-2 was incubated with human serum (1:4 dilution) instead of purified recombinant human MBL. For a negative control, purified human
MBL was diluted in 20 mM Tris-HCl (pH 7.4) and 150 mM NaCl supplemented with 40 mM EDTA or supplemented with 100 g/ml mannan. In
parallel experiments, captured DENV virions were detected by biotinylated anti-DENV E-protein-specific MAb 4G2 (55) (1 g/ml), followed by
HRP-conjugated streptavidin (2 g/ml).
MBL ELISA. The levels of MBL in serum were measured using an MBL
oligomer ELISA kit (BioPorto, Gentofte, Denmark) according to the
manufacturer’s instructions.
Hemolysis assay for serum C4. Serial dilutions of serum and purified
C4 (Complement Technology) were prepared in DGVB⫹⫹ (2.5 mM Bar-
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bital sodium, 139 mM dextrose, 71 mM NaCl, 0.1% [wt/vol] gelatin,
0.15 mM CaCl2, and 1 mM MgCl2). Ten microliters of diluted serum or a
C4 standard was added to a tube containing 476 l DGVB⫹⫹, 11 l of
antibody-coated sheep erythrocytes (EA) (5 ⫻ 108 cells/ml) (Complement Technology), and 3 l of C4-deficient guinea pig serum (Complement Technology). The tubes were incubated for 30 minutes at 37°C and
then centrifuged for 5 minutes at 830 ⫻ g. The OD of the supernatant was
measured at 414 nm. C4 concentrations were calculated from a standard
curve.
CH50 assay. The amount of hemolytic complement in serum was
measured by the method of Giclas (57) to obtain the CH50 values.
Statistical analysis. Data sets were compared using a two-tailed, unpaired t test. Multiple comparisons were performed using an analysis of
variance (ANOVA) test. Correlation coefficients were estimated based on
the Pearson product-moment correlation using Prism software (GraphPad Software). Statistical significance was achieved when P values were
⬍0.05.
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